Exelixis
1851 Harbor Bay Parkway, Alameda, CA, 94502, United States
Overview
Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
Investment portfolio
- Yummy
Participated · Equity · Oct 2022
Yummy is an Estonian startup that built a generative-AI platform to create and adapt recipes based on users' tastes, dietary restrictions, and budgets. Its software also generates images of dishes and offers variations such as faster, sweeter, low-calorie, or low-sodium versions. The company combines personalized meal planning and grocery-shopping features to deliver outcomes focused on taste, health, variety and minimizing food waste. Yummy began as a meal-kit business (Clean Kitchen) started by the co-founders in Estonia in 2020 and is opening its meal-kit service in Poland. The company raised a $3.6 million angel round from a collective of Estonian founders and angel investors to expand meal-kit availability and further develop its generative-AI features. Co-founder and CEO Martin Salo and CBO Karl Paadam emphasize that the AI will learn user preferences to automate recipe creation and simplify grocery shopping.